From: Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies
Pathology | Trial | Phase | No of. patients | Treatment | mPFS (months) | mOS (months) | ORR (%) | Other outcomes |
---|---|---|---|---|---|---|---|---|
Melanoma | KEYNOTE-006 | III | 834 | Pembrolizumab vs. Ipilimumab | 5.5 vs. 2.8 | – | 34 vs. 12 | – |
NSCLC | KEYNOTE-010 | II | – | Pembrolizumab vs. Docetaxel | 5.2 vs. 4.1 | 17.3 vs. 8.2 |  | – |
 | KEYNOTE-189 | III | 616 | Pembrolizumab + Pemetrexed and platinum vs. Placebo | 8.8 vs. 4.9 | – | 62.9 vs. 49.4 | – |
HNSCC | KEYNOTE-012 | Ib | 60 | Pembrolizumab | – | – | 18 | – |
UC | KEYNOTE-052 | II | 370 | Pembrolizumab | 2.0 | – | 24 | CR: 5%; DCR: 47% |
 | KEYNOTE-045 | III | 542 | Pembrolizumab vs. Paclitaxel and vinflunine | – | 10.3 vs. 7.4 | 21.1 vs. 11.4 | – |
cHL | KEYNOTE-087 | II | 210 | Pembrolizumab | 72.4%* | 99.5%* | 69 | CR: 22.4% |
PMBCL | KEYNOTE-170 | II | 49 | Pembrolizumab | – | 62%* | 41 | CR: 14%; PR: 28% |
DLBCL | Frigault et al | II | 29 | pembrolizumab | 59%* | 73%* |  | – |
MM | Badros et al | II | 48 | Pembrolizumab + Pomalidomide and Dexamethasone | – | – | 60 | CR: 8%; PR: 19% |
CC | KEYNOTE-028 | Ib | 24 | Pembrolizumab | 2.0 | 11.0 | 17 | DCR: 30% |
 | KEYNOTE-158 | II | 98 | Pembrolizumab | 2.1 | 9.4 | 13.3 | DCR: 30.6% |
Ovarian cancer | KEYNOTE-028 | II | 26 | Pembrolizumab | 1.9 | 13.8 | 11.5 | SD: 26.9% |
Endometrial cancer | Makker et al | II | 23 | Pembrolizumab + lenvatinib | – | – | 39.6 | DCR: 86.8% |
TNBC | KEYNOTE-086 | II | – | Pembrolizumab | 2.0 | 9.0 | 5.3 | DCR: 7.6% |
MSI-H and dMMRS | KEYNOTE-164 | II | 63 | Pembrolizumab | – | – | 26.2 | – |
PM | Cedrés et al | Ib | 25 | Pembrolizumab | – | – | 28 | SD: 48%; DCR: 76% |
GEJA | KEYNOTE-059 | II | 143 | Pembrolizumab | – | – | 13.3 | DOR: 16.3 months |
CRC | Ribas et al | Ib | – | Pembrolizumab + Oncolytic virus | – | – | 62 | CR: 33% |
HCC | KEYNOTE-224 | II | 104 | Pembrolizumab | – | 12.9 | 17 | CR: 1%; PR: 16%; DCR: 60% |